Arcturus Therapeutics (NASDAQ:ARCT) Downgraded by Wall Street Zen to “Strong Sell”

Wall Street Zen downgraded shares of Arcturus Therapeutics (NASDAQ:ARCT) from a sell rating to a strong sell rating in a research note published on Saturday.

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Arcturus Therapeutics in a research note on Friday, July 17th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $24.25.

Arcturus Therapeutics Trading Down 2.7%

NASDAQ:ARCT opened at $5.76 on Friday. The firm has a 50-day moving average price of $6.89 and a two-hundred day moving average price of $7.43. Arcturus Therapeutics has a twelve month low of $5.50 and a twelve month high of $24.17. The company has a market capitalization of $163.70 million, a P/E ratio of -2.05 and a beta of 2.37.

Arcturus Therapeutics (NASDAQ:ARCT) last announced its quarterly earnings results on Friday, May 8th. The biotechnology company reported ($0.95) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.03) by $0.08. The company had revenue of $2.06 million for the quarter, compared to the consensus estimate of $6.30 million. Arcturus Therapeutics had a negative net margin of 143.80% and a negative return on equity of 36.55%. On average, equities research analysts predict that Arcturus Therapeutics will post -3.99 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in ARCT. Osaic Holdings Inc. lifted its holdings in Arcturus Therapeutics by 51.8% in the 2nd quarter. Osaic Holdings Inc. now owns 2,163 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 738 shares in the last quarter. CANADA LIFE ASSURANCE Co grew its holdings in shares of Arcturus Therapeutics by 27.5% during the third quarter. CANADA LIFE ASSURANCE Co now owns 7,272 shares of the biotechnology company’s stock worth $136,000 after buying an additional 1,567 shares in the last quarter. Bank of America Corp DE grew its holdings in shares of Arcturus Therapeutics by 0.7% during the second quarter. Bank of America Corp DE now owns 292,429 shares of the biotechnology company’s stock worth $3,805,000 after buying an additional 2,098 shares in the last quarter. BNP Paribas Financial Markets grew its holdings in shares of Arcturus Therapeutics by 163.4% during the second quarter. BNP Paribas Financial Markets now owns 4,169 shares of the biotechnology company’s stock worth $54,000 after buying an additional 2,586 shares in the last quarter. Finally, Two Sigma Investments LP raised its position in shares of Arcturus Therapeutics by 3.3% in the third quarter. Two Sigma Investments LP now owns 89,219 shares of the biotechnology company’s stock valued at $1,644,000 after buying an additional 2,857 shares during the last quarter. Institutional investors and hedge funds own 94.54% of the company’s stock.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc is a clinical-stage biotechnology company dedicated to developing messenger RNA (mRNA) medicines that address a range of diseases. The company leverages its proprietary STARR® mRNA platform to enable precise control over mRNA expression, supported by its lipid nanoparticle delivery technology, LUNAR®. Arcturus’s approach is designed to address both therapeutic and prophylactic applications, with an emphasis on vaccines and treatments for rare genetic and infectious diseases.

The company’s pipeline includes ARCT-810, an mRNA therapeutic candidate for phenylketonuria (PKU), and ARCT-021 (also known as LUNAR-COV19), a COVID-19 vaccine candidate developed in collaboration with Duke-NUS Medical School in Singapore.